Immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD-1) or its ligand, programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), have become the backbone of cancer therapy for a multitude of solid tumors. The gene discussed is CD274; the disease is cancer.